Robbins Arroyo LLP: Antares Pharma, Inc. (ATRS) Misled Shareholders According to a Class Action

Stock Information for Antares Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Antares Pharma Inc.

Antares Pharma Reports Second Quarter 2018 Operating and Financial Results
Antares Pharma Appoints Dr. James Tursi Executive Vice President, Head of Research & Development, Chief Medical Officer
Antares Pharma Enters Into Development Agreement With Pfizer Inc.
Antares Pharma to Report Second Quarter 2018 Financial and Operating Results
Consolidated Research: 2018 Summary Expectations for South Jersey Industries, Cedar Realty Trust, Antares Pharma, Q2, Cree, and HCI Group - Fundamental Analysis, Key Performance Indications
Antares Pharma Announces Receipt of Third Installment From Sale of ZOMAJET(TM) Needle-Free Delivery System
Antares Pharma to Present at the Jefferies 2018 Healthcare Conference
Antares Pharma Reports First Quarter 2018 Operating and Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.